Renske M. van ’t Oever
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Renske M. van ’t Oever has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Ejt Joanne Verweij
Department of Obstetrics Leiden University Medical Center Leiden The Netherlands
3 shared publications - Masja de Haas
Department of Immunohematology Diagnostics Sanquin Diagnostic Services Amsterdam The Netherlands
3 shared publications Carolien Zwiers
Division of Fetal Therapy, Department of Obstetrics Leiden University Medical Centre Leiden The Netherlands
2 shared publicationsDick Oepkes
Division of Fetal Therapy, Department of Obstetrics Leiden University Medical Centre Leiden The Netherlands
2 shared publications- Enrico Lopriore
Division of Neonatology, Department of Pediatrics, Willem‐Alexander Children's Hospital Leiden University Medical Center Leiden the Netherlands
2 shared publications Masja de Haas
Translational Immunohaematology Sanquin Research and Landsteiner Laboratory Amsterdam UMC Amsterdam The Netherlands
2 shared publications
Latest Publications
- Open Access
- 10 February 2026
- Published by Wiley in Vox Sanguinis
- Vol. 121 (3) , 361-369
Routine use of a spike‐in DNA in‐process control for foetal RHD genotyping: Testing the real‐world effectiveness of this ‘canary’
Background and Objectives: Non‐invasive foetal RHD ( fRHD ) genotyping is widely implemented to prevent unnecessary administration of antenatal anti‐D prophylaxis. Reliable assay performance is critical. In line with expert recommendations, we validated and implemented an artificial spike‐in extraction control in our previously published assay. In this study, we report on assay verification and its performance in a 2‐year cohort. Study Design and Methods: fRHD typing was performed with cell‐free DNA isolated from maternal plasma from gestational age week 27 or later. A circular plasmid with a fragment of glycoprotein B gene of the Phocid herpes virus type 1 (PhHV1‐gB) (spike‐in control) was added to the plasma before DNA extraction. Assay accuracy was verified with gestational week‐27 plasma samples and corresponding cord blood samples from D‐negative pregnant women. In addition, assay performance over time was evaluated in a 2‐year cohort. Results: The performance verification of our modified assay showed no false negative and one false positive test result in a small clinical cohort ( n = 191). In a further 47,391 samples across 1111 runs, we observed eight false negative results due to technical failures that were prevented by the addition of the spike‐in control. In this larger series, the spike‐in control was the sole detector of a technical problem most likely related to different batches of the DNA extraction kit. Conclusion: This study demonstrates the prevention of false negative fRHD typing results by the addition of an artificial extraction control. This control allows improved monitoring of assay performance, thereby ensuring assay consistency. Findings underscore the importance of thorough quality assurance measures in fRHD genotyping.
- 10 February 2026
- Published by Wiley in Vox Sanguinis
- Vol. 121 (3) , 361-369
Open AccessRoutine use of a spike‐in DNA in‐process control for foetal RHD genotyping: Testing the real‐world effectiveness of this ‘canary’
Background and Objectives: Non‐invasive foetal RHD ( fRHD ) genotyping is widely implemented to prevent unnecessary administration of antenatal anti‐D prophylaxis. Reliable assay performance is critical. In line with expert recommendations, we validated and implemented an artificial spike‐in extraction control in our previously published assay. In this study, we report on assay verification and its performance in a 2‐year cohort. Study Design and Methods: fRHD typing was performed with cell‐free DNA isolated from maternal plasma from gestational age week 27 or later. A circular plasmid with a fragment of glycoprotein B gene of the Phocid herpes virus type 1 (PhHV1‐gB) (spike‐in control) was added to the plasma before DNA extraction. Assay accuracy was verified with gestational week‐27 plasma samples and corresponding cord blood samples from D‐negative pregnant women. In addition, assay performance over time was evaluated in a 2‐year cohort. Results: The performance verification of our modified assay showed no false negative and one false positive test result in a small clinical cohort ( n = 191). In a further 47,391 samples across 1111 runs, we observed eight false negative results due to technical failures that were prevented by the addition of the spike‐in control. In this larger series, the spike‐in control was the sole detector of a technical problem most likely related to different batches of the DNA extraction kit. Conclusion: This study demonstrates the prevention of false negative fRHD typing results by the addition of an artificial extraction control. This control allows improved monitoring of assay performance, thereby ensuring assay consistency. Findings underscore the importance of thorough quality assurance measures in fRHD genotyping.
- 15 May 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (20) , 2266-2274
How I use noninvasive prenatal testing for red blood cell and platelet antigens
Alloimmunization during pregnancy occurs when a mother produces antibodies against fetal antigens, leading to complications like hemolytic disease of the fetus and newborn (HDFN) and fetal and neonatal alloimmune thrombocytopenia (FNAIT). HDFN involves destruction of fetal red blood cells, potentially causing severe anemia, hydrops fetalis, and fetal death. FNAIT affects fetal platelets and possibly endothelial cells, resulting in risk of intracranial hemorrhage and brain damage. Traditional invasive methods for fetal antigen genotyping, like amniocentesis, carried miscarriage risks. The discovery of cell-free fetal DNA (cff-DNA) in maternal plasma enabled safe, noninvasive prenatal testing (NIPT). Initially used for Rhesus antigen D blood group typing, NIPT now covers various blood group antigens. Advances in technology have further enhanced the accuracy of NIPT. Despite challenges such as low cff-DNA fractions and complex genetic variations, NIPT has become essential in managing alloimmunized pregnancies. In NIPT it is important to prevent both false-positive results and false-negative results. Particularly in the coming decades, more possibilities for personalized antenatal treatment for HDFN and FNAIT cases will become apparent and accurate NIPT blood group antigen typing results are crucial for guiding clinical decisions. In this paper we describe this journey and provide practical tools for the clinic.
- 15 May 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (20) , 2266-2274
How I use noninvasive prenatal testing for red blood cell and platelet antigens
Alloimmunization during pregnancy occurs when a mother produces antibodies against fetal antigens, leading to complications like hemolytic disease of the fetus and newborn (HDFN) and fetal and neonatal alloimmune thrombocytopenia (FNAIT). HDFN involves destruction of fetal red blood cells, potentially causing severe anemia, hydrops fetalis, and fetal death. FNAIT affects fetal platelets and possibly endothelial cells, resulting in risk of intracranial hemorrhage and brain damage. Traditional invasive methods for fetal antigen genotyping, like amniocentesis, carried miscarriage risks. The discovery of cell-free fetal DNA (cff-DNA) in maternal plasma enabled safe, noninvasive prenatal testing (NIPT). Initially used for Rhesus antigen D blood group typing, NIPT now covers various blood group antigens. Advances in technology have further enhanced the accuracy of NIPT. Despite challenges such as low cff-DNA fractions and complex genetic variations, NIPT has become essential in managing alloimmunized pregnancies. In NIPT it is important to prevent both false-positive results and false-negative results. Particularly in the coming decades, more possibilities for personalized antenatal treatment for HDFN and FNAIT cases will become apparent and accurate NIPT blood group antigen typing results are crucial for guiding clinical decisions. In this paper we describe this journey and provide practical tools for the clinic.
- Open Access
- 27 March 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 65 (5) , 589-596
Comparison of intrauterine transfusion techniques in hemolytic disease of the fetus and newborn
Objectives: Intrauterine transfusions (IUTs) are the cornerstone in treatment for hemolytic disease of the fetus and newborn (HDFN). It has been suggested that a non‐vascular intraperitoneal blood transfusion used in conjunction with an intravascular IUT can slow the decrease in fetal hemoglobin (Hb) levels, potentially extending the interval between transfusions. Our aim was to evaluate the rate of decline in Hb levels and the interval between transfusions using different IUT techniques, including intrahepatic transfusions with and without intraperitoneal transfusion, and transplacental transfusion at the site of the placental cord insertion.Methods: We conducted a retrospective cohort study at the Leiden University Medical Center, the national referral center for HDFN, between January 2006 and December 2022. All cases that underwent intrahepatic (with and without intraperitoneal transfusion) and placental cord insertion IUTs during the study period were included. The primary outcome was the decline in Hb levels per week, measured by comparing the Hb level immediately after the IUT with the Hb level before the subsequent IUT or birth. The primary outcome was analyzed using generalized estimating equations with and without adjustment for confounders.Results: We included 309 fetuses that received a total of 791 IUTs, of which 151 were intrahepatic‐only transfusions, 273 were intrahepatic + intraperitoneal transfusions and 367 were placental cord insertion transfusions. We found an adjusted mean difference in the decline in Hb levels of 0.48 (95% CI, 0.29–0.66) g/dL/week between the group that underwent intrahepatic‐only transfusion and the group that underwent intrahepatic + intraperitoneal transfusion (P < 0.001). The adjusted mean difference between the intrahepatic‐only IUT group and the placental cord insertion IUT group was 0.49 (95% CI, 0.05–0.94) g/dL/week (P = 0.030). The median interval to the next IUT for the total cohort was 21 (interquartile range (IQR), 18–28) days. Similarly, in the intrahepatic‐only and placental cord insertion IUT groups, the median interval to the next IUT was 21 (IQR, 19–28) and 21 (IQR, 15–26) days, respectively. In the intrahepatic + intraperitoneal transfusion group, the median interval was slightly higher (26 (IQR, 21–28) days).Conclusion: Decline in Hb levels was slower when using intrahepatic + intraperitoneal transfusion compared with other IUT techniques and seemed to prolong the interval between IUT procedures. The potential clinical advantages of the intrahepatic + intraperitoneal transfusion technique need to be weighed against the increased complexity and extended duration of the procedure on an individual basis. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- 27 March 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 65 (5) , 589-596
Open AccessComparison of intrauterine transfusion techniques in hemolytic disease of the fetus and newborn
Objectives: Intrauterine transfusions (IUTs) are the cornerstone in treatment for hemolytic disease of the fetus and newborn (HDFN). It has been suggested that a non‐vascular intraperitoneal blood transfusion used in conjunction with an intravascular IUT can slow the decrease in fetal hemoglobin (Hb) levels, potentially extending the interval between transfusions. Our aim was to evaluate the rate of decline in Hb levels and the interval between transfusions using different IUT techniques, including intrahepatic transfusions with and without intraperitoneal transfusion, and transplacental transfusion at the site of the placental cord insertion.Methods: We conducted a retrospective cohort study at the Leiden University Medical Center, the national referral center for HDFN, between January 2006 and December 2022. All cases that underwent intrahepatic (with and without intraperitoneal transfusion) and placental cord insertion IUTs during the study period were included. The primary outcome was the decline in Hb levels per week, measured by comparing the Hb level immediately after the IUT with the Hb level before the subsequent IUT or birth. The primary outcome was analyzed using generalized estimating equations with and without adjustment for confounders.Results: We included 309 fetuses that received a total of 791 IUTs, of which 151 were intrahepatic‐only transfusions, 273 were intrahepatic + intraperitoneal transfusions and 367 were placental cord insertion transfusions. We found an adjusted mean difference in the decline in Hb levels of 0.48 (95% CI, 0.29–0.66) g/dL/week between the group that underwent intrahepatic‐only transfusion and the group that underwent intrahepatic + intraperitoneal transfusion (P < 0.001). The adjusted mean difference between the intrahepatic‐only IUT group and the placental cord insertion IUT group was 0.49 (95% CI, 0.05–0.94) g/dL/week (P = 0.030). The median interval to the next IUT for the total cohort was 21 (interquartile range (IQR), 18–28) days. Similarly, in the intrahepatic‐only and placental cord insertion IUT groups, the median interval to the next IUT was 21 (IQR, 19–28) and 21 (IQR, 15–26) days, respectively. In the intrahepatic + intraperitoneal transfusion group, the median interval was slightly higher (26 (IQR, 21–28) days).Conclusion: Decline in Hb levels was slower when using intrahepatic + intraperitoneal transfusion compared with other IUT techniques and seemed to prolong the interval between IUT procedures. The potential clinical advantages of the intrahepatic + intraperitoneal transfusion technique need to be weighed against the increased complexity and extended duration of the procedure on an individual basis. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- Open Access
- 24 September 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 131 (6) , 769-776
Severity of haemolytic disease of the fetus and newborn in patients with a history of intrauterine transfusions in a previous pregnancy: A nationwide retrospective cohort study
Objective: Pregnant women who received at least one intrauterine transfusion (IUT) for haemolytic disease of the fetus and newborn (HDFN) in the preceding pregnancy are presumed to have a high likelihood of requiring IUTs again, often starting at an earlier gestational age. Our aim was to quantify these risks in a large national cohort.Design: Retrospective cohort study of a nationwide Dutch database.Setting: The Netherlands.Population: All women treated in The Netherlands with IUTs for Rhesus D (RhD)‐ or Kell‐mediated HDFN between 1999 and 2017 and their follow‐up pregnancies were included. Pregnancies with an antigen‐negative fetus were excluded.Methods: Electronic patient files were searched for the number and gestational age of each IUT, and analysed using descriptive statistics and linear regression.Main outcome measures: Percentage of women requiring one or more IUTs again in the subsequent pregnancy, and gestational age at first IUT in both pregnancies.Results: Of the 321 women in our study population, 21% (69) had a subsequent ongoing pregnancy at risk. IUTs were administered in 86% (59/69) of cases. In subsequent pregnancies, the median gestational age at first IUT was 3 weeks earlier (interquartile range −6.8 to 0.4) than in the preceding pregnancy.Conclusions: Our study shows that pregnant women with a history of IUTs in the previous pregnancy are highly likely to require IUTs again, and on average 3 weeks earlier. Clinicians need to be aware of these risks and ensure timely referral, and close surveillance from early pregnancy onwards. Additionally, for women with a history of IUT and their caregivers, this information is essential to enable adequate preconception counselling.
- 24 September 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 131 (6) , 769-776
Open AccessSeverity of haemolytic disease of the fetus and newborn in patients with a history of intrauterine transfusions in a previous pregnancy: A nationwide retrospective cohort study
Objective: Pregnant women who received at least one intrauterine transfusion (IUT) for haemolytic disease of the fetus and newborn (HDFN) in the preceding pregnancy are presumed to have a high likelihood of requiring IUTs again, often starting at an earlier gestational age. Our aim was to quantify these risks in a large national cohort.Design: Retrospective cohort study of a nationwide Dutch database.Setting: The Netherlands.Population: All women treated in The Netherlands with IUTs for Rhesus D (RhD)‐ or Kell‐mediated HDFN between 1999 and 2017 and their follow‐up pregnancies were included. Pregnancies with an antigen‐negative fetus were excluded.Methods: Electronic patient files were searched for the number and gestational age of each IUT, and analysed using descriptive statistics and linear regression.Main outcome measures: Percentage of women requiring one or more IUTs again in the subsequent pregnancy, and gestational age at first IUT in both pregnancies.Results: Of the 321 women in our study population, 21% (69) had a subsequent ongoing pregnancy at risk. IUTs were administered in 86% (59/69) of cases. In subsequent pregnancies, the median gestational age at first IUT was 3 weeks earlier (interquartile range −6.8 to 0.4) than in the preceding pregnancy.Conclusions: Our study shows that pregnant women with a history of IUTs in the previous pregnancy are highly likely to require IUTs again, and on average 3 weeks earlier. Clinicians need to be aware of these risks and ensure timely referral, and close surveillance from early pregnancy onwards. Additionally, for women with a history of IUT and their caregivers, this information is essential to enable adequate preconception counselling.
- 5 December 2022
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 182 (2) , 489-500
History and current standard of postnatal management in hemolytic disease of the fetus and newborn
Since the discovery of the Rh blood group system in 1940, a greater understanding of hemolytic disease of the fetus and newborn (HDFN) was gained. In the years thereafter, researchers and clinicians came to the current understanding that fetal and neonatal red blood cells (RBC) are hemolyzed by maternal alloantibodies directed against RBC antigens potentially leading to severe disease. Preventative measures, such as Rhesus(D) immunoprophylaxis (RhIG), have greatly decreased the prevalence of Rh(D)-mediated HDFN, although a gap between high-income countries and middle- to low-income countries was created largely due to a lack in availability and high costs of RhIG. Other important developments in the past decades have improved the identification, monitoring, and care of pregnancies, fetuses, and neonates with HDFN. Prenatally, fetal anemia may occur and intrauterine transfusions may be needed. Postnatally, pediatricians should be aware of the (antenatally determined) risk of hemolysis in RBC alloimmunization and should provide treatment for hyperbilirubinemia in the early phase and monitor for anemia in the late phase of the disease. Through this review, we aim to provide an overview of important historic events and to provide hands-on guidelines for the delivery and postnatal management of neonates with HDFN. Secondarily, we aim to describe recent scientific findings and evidence gaps. Conclusion: Multiple developments have improved the identification, monitoring, and care of pregnancies and neonates with HDFN throughout the centuries. Pediatricians should be aware of the (antenatally determined) risk of hemolysis in RBC alloimmunization and should provide treatment for hyperbilirubinemia in the early phase and monitor for late anemia in the late phase of the disease. Future studies should be set in an international setting and ultimately aim to eradicate HDFN on a global scale. What is Known: • Developments have led to a greater understanding of the pathophysiology, an improved serological identification and monitoring of at-risk cases and the current pre- and postnatal treatment. What is New: • This review provides the pediatrician with hands-on guidelines for the delivery and postnatal management of neonates with HDFN. • Future studies should be set in an international setting with the ultimate aim of eradicating HDFN.
- 5 December 2022
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 182 (2) , 489-500
History and current standard of postnatal management in hemolytic disease of the fetus and newborn
Since the discovery of the Rh blood group system in 1940, a greater understanding of hemolytic disease of the fetus and newborn (HDFN) was gained. In the years thereafter, researchers and clinicians came to the current understanding that fetal and neonatal red blood cells (RBC) are hemolyzed by maternal alloantibodies directed against RBC antigens potentially leading to severe disease. Preventative measures, such as Rhesus(D) immunoprophylaxis (RhIG), have greatly decreased the prevalence of Rh(D)-mediated HDFN, although a gap between high-income countries and middle- to low-income countries was created largely due to a lack in availability and high costs of RhIG. Other important developments in the past decades have improved the identification, monitoring, and care of pregnancies, fetuses, and neonates with HDFN. Prenatally, fetal anemia may occur and intrauterine transfusions may be needed. Postnatally, pediatricians should be aware of the (antenatally determined) risk of hemolysis in RBC alloimmunization and should provide treatment for hyperbilirubinemia in the early phase and monitor for anemia in the late phase of the disease. Through this review, we aim to provide an overview of important historic events and to provide hands-on guidelines for the delivery and postnatal management of neonates with HDFN. Secondarily, we aim to describe recent scientific findings and evidence gaps. Conclusion: Multiple developments have improved the identification, monitoring, and care of pregnancies and neonates with HDFN throughout the centuries. Pediatricians should be aware of the (antenatally determined) risk of hemolysis in RBC alloimmunization and should provide treatment for hyperbilirubinemia in the early phase and monitor for late anemia in the late phase of the disease. Future studies should be set in an international setting and ultimately aim to eradicate HDFN on a global scale. What is Known: • Developments have led to a greater understanding of the pathophysiology, an improved serological identification and monitoring of at-risk cases and the current pre- and postnatal treatment. What is New: • This review provides the pediatrician with hands-on guidelines for the delivery and postnatal management of neonates with HDFN. • Future studies should be set in an international setting with the ultimate aim of eradicating HDFN.
- Open Access
- 31 October 2022
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 15 (11) , 987-998
Identification and management of fetal anemia due to hemolytic disease
Hemolytic disease of the fetus and newborn (HDFN) is a condition caused by maternal alloantibodies against fetal red blood cells (RBCs) that can cause severe morbidity and mortality in the fetus an...
- 31 October 2022
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 15 (11) , 987-998
Open AccessIdentification and management of fetal anemia due to hemolytic disease
Hemolytic disease of the fetus and newborn (HDFN) is a condition caused by maternal alloantibodies against fetal red blood cells (RBCs) that can cause severe morbidity and mortality in the fetus an...